Kovalchuk V V, Ershova I I, Molodovskaya N V
Semashko City Hospital No. 38, St. Petersburg, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(3. Vyp. 2):60-66. doi: 10.17116/jnevro202112103260.
To study the possibility of improving the efficacy of treatment with mexidol in COVID-19 patients with chronic cerebral ischemia (CCI).
Three hundred and four patients with CCI and COVID-19 were observed, group 1 (=152) consisted of patients receiving basic therapy and mexidol, group 2 (=152) received only basic therapy. Mexidol was administered intravenously for 14 days, 500 mg (10 ml) per 400 ml of saline solution, then Mexidol FORTE 250 was administered in a dose of 250 mg 3 times a day for 2 months. The state of cognitive functions (MoCA scale), sleep (Spiegel questionnaire), asthenia (MFI-20 scale), and quality of life (SIP questionnaire) were evaluated. Examinations were performed before treatment, 30 and 75 days after start of treatment.
In group 1, there was a more complete and earlier recovery of the state of cognitive functions (an increase in indicators on the MoCA scale, <0.01), a regression of asthenia (<0.05), and normalization of sleep (<0.01). By the end of the study, there were significantly more patients in group 1 with complete or significant recovery of all quality of life indicators.
Long-term sequential therapy with mexidol provides a more complete recovery of impaired functions in patients with CCI and COVID-19.
研究提高美西多宁对合并慢性脑缺血（CCI）的新型冠状病毒肺炎（COVID-19）患者治疗效果的可能性。
观察304例合并CCI的COVID-19患者，第1组（n = 152）患者接受基础治疗和美西多宁，第2组（n = 152）仅接受基础治疗。美西多宁静脉滴注14天，每400 ml生理盐水加500 mg（10 ml），之后服用美西多宁强力型250，剂量为250 mg，每日3次，持续2个月。评估认知功能状态（蒙特利尔认知评估量表）、睡眠（斯皮格尔问卷）、乏力（MFI-20量表）及生活质量（SIP问卷）。在治疗前、治疗开始后30天和75天进行检查。
第1组认知功能状态恢复更完全且更早（蒙特利尔认知评估量表指标升高，P<0.01），乏力症状减轻（P<0.05），睡眠恢复正常（P<0.01）。到研究结束时，第1组中所有生活质量指标完全或显著恢复的患者明显更多。
美西多宁长期序贯治疗能使合并CCI的COVID-19患者受损功能更完全恢复。
